AVDL · As filed with the SEC
Avadel Pharmaceuticals cash flow statement, by fiscal year
The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | (48,832) | (160,276) | (137,464) | (77,329) | 7,028 | (33,226) | (95,304) | 68,271 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 2,681 | 1,766 | 1,493 | 815 | 1,690 | 2,486 | 7,430 | 4,883 |
| Loss on disposal of property and equipment | — | — | — | — | — | — | — | 0 |
| Impairment of intangible asset | — | — | — | — | 0 | 0 | 66,087 | — |
| Amortization of premiums on marketable securities | — | — | — | — | — | 41 | 2,823 | (411) |
| Foreign exchange loss (gain) | — | — | — | — | — | — | — | 714 |
| Grants recognized in research and development expenses | — | — | — | — | — | — | — | (539) |
| Remeasurement of acquisition-related contingent consideration | — | — | — | 0 | 3,327 | 845 | (22,731) | (31,040) |
| Remeasurement of financing-related contingent consideration | — | — | — | 0 | 435 | 378 | (1,899) | (2,071) |
| Amortization of debt discount and debt issuance costs | 0 | 2,796 | 6,052 | 1,248 | 6,524 | 5,995 | 4,830 | — |
| Changes in deferred taxes | 0 | 0 | 26,025 | (15,666) | (7,431) | (6,334) | (19,152) | 3,556 |
| Share-based compensation expense | 20,387 | 15,811 | 7,013 | 8,872 | 2,999 | 519 | 7,852 | 8,072 |
| Gain on sale of Hospital Products | — | — | — | 0 | (45,760) | — | — | — |
| Loss on deconsolidation of subsidiary | — | — | — | 0 | 0 | 1,750 | — | — |
| Gain from release of certain liabilities | — | — | — | (217) | (3,364) | — | — | — |
| Loss on extinguishment of debt | 0 | 13,129 | — | — | — | — | — | — |
| Other adjustments | (828) | 1,262 | 2,042 | 1,272 | 142 | (295) | 1,365 | — |
| Net changes in assets and liabilities | ||||||||
| Accounts receivable | (21,994) | (12,103) | — | 0 | 8,281 | 2,471 | 3,452 | 3,054 |
| Inventories | (9,219) | (9,532) | — | 0 | (1,352) | 1,155 | 711 | (2,899) |
| Prepaid expenses and other current assets | 416 | (3,127) | 30,815 | (439) | 1,863 | (1,187) | 3,577 | (3,741) |
| Research and development tax credit receivable | — | 1,884 | 30 | 2,796 | 2,213 | (1,014) | (2,545) | (3,141) |
| Accounts payable & other current liabilities | (4,093) | 1,545 | (3,108) | 4,232 | (2,788) | 4,641 | (2,032) | 595 |
| Deferred revenue | — | — | — | — | — | — | — | (216) |
| Deferred revenue | — | — | — | 0 | 0 | (114) | (1,892) | — |
| Accrued expenses | 16,424 | 16,892 | 227 | 895 | (13,226) | 357 | (10,640) | 13,187 |
| Accrued income taxes | — | — | — | — | — | (30) | (341) | (786) |
| Earn-out payments for contingent consideration in excess of acquisition-date fair value | — | — | — | 0 | (5,323) | (10,988) | (19,468) | (31,636) |
| Royalty payments for contingent consideration payable in excess of original fair value | — | — | — | 0 | (866) | (1,748) | (2,838) | (4,429) |
| Other assets and liabilities | (1,849) | 1,442 | (3,429) | (3,789) | (3,126) | (4,027) | (2,001) | (4,761) |
| Net cash used in operating activities | (46,907) | (128,511) | (70,304) | (77,310) | (48,734) | (38,325) | (82,716) | 16,662 |
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | 0 | 0 | (716) | (26) | (98) | (29) | (178) | (591) |
| Acquisitions of businesses, including cash acquired and other adjustments | — | — | — | — | — | — | 0 | 0 |
| Proceeds from disposal of property and equipment | — | — | — | 0 | 0 | 154 | — | — |
| Proceeds from the disposition of the Hospital Products | — | 0 | 0 | 16,500 | 25,500 | — | — | — |
| Purchase of intangible assets | — | — | — | — | 0 | 0 | (20,000) | (53,111) |
| Proceeds from sales of marketable securities | — | — | — | — | — | — | — | 189,009 |
| Proceeds from sales of marketable securities | 327,781 | 187,136 | 83,828 | 102,224 | 36,284 | 63,246 | 359,507 | — |
| Purchases of marketable securities | (276,001) | (237,229) | (3,414) | (61,769) | (131,407) | (24,648) | (376,310) | (151,005) |
| Net cash provided by (used in) investing activities | 51,780 | (50,093) | 79,698 | 56,929 | (69,721) | 38,723 | (36,981) | (15,698) |
| Cash flows from financing activities: | ||||||||
| Reimbursement of loans | — | — | — | — | — | — | — | 0 |
| Proceeds from the February 2020 private placement | — | — | — | 0 | 60,570 | — | — | — |
| Proceeds from the May 2020 public offering | — | — | — | 0 | 116,924 | — | — | — |
| Proceeds from issuance of shares, net of issue costs | — | — | 25,318 | — | — | — | — | — |
| At-the-market offering program | 9,250 | 11,913 | — | — | — | — | — | — |
| Public offering | 0 | 134,151 | — | — | — | — | — | — |
| Proceeds from stock option exercises and employee share purchase plan | 6,720 | 2,293 | 2,682 | 263 | 2,189 | — | — | — |
| Share repurchases | — | — | — | — | 0 | 0 | (27,637) | (22,361) |
| Other financing activities, net | — | — | — | 0 | 0 | (145) | (107) | — |
| February 2023 Notes | 0 | (17,500) | — | — | — | — | — | — |
| October 2023 Notes | 0 | (21,165) | — | — | — | — | — | — |
| Payments for debt issuance costs | 0 | (4,357) | (4,804) | — | — | — | — | — |
| Payments for extinguishment of February 2023 Notes | — | — | (8,653) | — | — | — | — | — |
| Proceeds from royalty purchase agreement | 0 | 30,000 | — | — | 0 | 0 | 143,750 | — |
| Payments for debt issuance costs | — | — | — | — | 0 | 0 | (6,190) | (115) |
| Earn-out payments for related party contingent consideration | — | — | — | — | — | 0 | (645) | (1,246) |
| Royalty payments for related party payable | — | — | — | — | — | — | 0 | 0 |
| Exercise of warrants | — | — | — | — | 0 | 0 | 2,911 | 0 |
| Proceeds from issuance of ordinary shares | — | — | — | — | — | 118 | 577 | 404 |
| Net cash provided by financing activities | 15,970 | 135,335 | 14,543 | 263 | 179,683 | (27) | 112,659 | (23,318) |
| Effect of foreign currency exchange rate changes on cash and cash equivalents | — | — | — | — | — | — | (201) | (297) |
| Net change in cash and cash equivalents | — | — | — | — | — | — | (7,239) | (22,651) |
| Cash and cash equivalents at January 1 | — | — | — | — | — | 9,325 | 16,564 | 39,215 |
| Cash and cash equivalents at December 31 | — | — | — | — | — | — | 9,325 | 16,564 |
| Effect of foreign currency exchange rate changes on cash and cash equivalents | (639) | 455 | (664) | (896) | 720 | 78 | — | — |
| Net change in cash and cash equivalents | 20,204 | (42,814) | 23,273 | (21,014) | 61,948 | 449 | — | — |
| Cash and cash equivalents at January 1 | 31,167 | 73,981 | 50,708 | 71,722 | 9,774 | 9,325 | 16,564 | — |
| Cash and cash equivalents at December 31 | 51,371 | 31,167 | 73,981 | 50,708 | 71,722 | 9,774 | — | — |
| Supplemental disclosures of cash flow information: | ||||||||
| Income tax paid | — | — | — | — | — | 140 | 776 | 19,143 |
| Interest paid | — | — | — | — | — | — | — | 1,050 |
| Interest paid | 7,181 | 5,250 | 9,660 | 6,469 | 6,469 | 6,469 | 3,359 | — |
| Income taxes refunded, net | 0 | 0 | (29,058) | 76 | (1,701) | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.